1. Home
  2. CNS vs PTCT Comparison

CNS vs PTCT Comparison

Compare CNS & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

HOLD

Current Price

$62.29

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$77.48

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNS
PTCT
Founded
1986
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
5.3B
IPO Year
2004
2013

Fundamental Metrics

Financial Performance
Metric
CNS
PTCT
Price
$62.29
$77.48
Analyst Decision
Hold
Buy
Analyst Count
2
17
Target Price
$72.50
$73.76
AVG Volume (30 Days)
535.9K
2.3M
Earning Date
01-21-2026
11-04-2025
Dividend Yield
3.99%
N/A
EPS Growth
18.87
N/A
EPS
3.19
8.94
Revenue
$552,096,000.00
$1,779,150,000.00
Revenue This Year
$8.26
$128.32
Revenue Next Year
$10.55
N/A
P/E Ratio
$19.51
$8.64
Revenue Growth
11.13
97.54
52 Week Low
$58.80
$35.95
52 Week High
$102.57
$87.50

Technical Indicators

Market Signals
Indicator
CNS
PTCT
Relative Strength Index (RSI) 42.45 54.29
Support Level $61.59 $73.03
Resistance Level $64.43 $79.03
Average True Range (ATR) 1.82 3.38
MACD 0.21 -0.70
Stochastic Oscillator 57.52 29.37

Price Performance

Historical Comparison
CNS
PTCT

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

Share on Social Networks: